Aer Therapeutics

Aer Therapeutics is a clinical-stage biopharmaceutical company with the mission of developing novel treatments for mucus-related pulmonary diseases. The company leverages the expertise of its scientific founders in airway mucus biology and pathology, drug glycochemistry, and inhaled therapeutics, as well as the experience of its management team in pulmonary drug development. Its lead candidate drug, AER-01, will enter Phase 1 clinical trials in 2023, with the potential to expand into various other indications such as asthma, bronchiectasis, and cystic fibrosis.